A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Acetyl hexapeptide-8

Cosmetic ingredient

Cosmetic signal-blocking peptide

Also known as: Argireline, acetyl hexapeptide-3, Acetyl hexapeptide-3, Argireline NP, Hexapeptide 3, Acetyl hexapeptide 3, Acetyl-glu-glu-met-gln-arg-arg-amide

Evidence score

50/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. Cosmetic ingredient, not regulated as a drug
Limited human data. Some human data exists, not conclusive
Registered human trials. 6 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Acetyl hexapeptide-8, widely sold as Argireline, is a short synthetic peptide used in topical skin care products. It is modeled on a fragment of SNAP-25, a protein involved in nerve signaling to muscles, and is thought to partly interfere with the signals that cause facial muscle contraction, which is why it is often marketed for expression lines.

What the evidence shows

Automatic summaryLimited human data

It is regulated as a cosmetic ingredient, not an approved drug, and has no FDA-approved indication. A small number of human studies, including six registered trials, suggest modest effects on the appearance of wrinkles, but the studies are generally small, often industry linked, and it remains unclear how well the peptide penetrates skin or how its effects compare with established treatments.